Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase II) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase Ib). With AM-301, Auris is developing a nasal spray for protection against airborne pathogens and allergens.
In this video, Auris founder and chief executive officer Thomas Meyer provides an update on the company’s lead programs, AM-125 and AM-201, discussing recently received positive data and outlining key milestones for Q4 and 2021. Thomas also introduces the company’s new program, AM-301, and discusses the how the establishment of its new subsidiary, Altamira Medica, will support this ongoing development.